A 39-year-old woman presented with loose stool and rectal bleeding for 1 year. A colonoscopy was performed and revealed proctitis. Rectal biopsy revealed a diagnosis of rectal marginal B-cell lymphoma of mucosa-associated lymphoid tissue (MALT). She was treated with a course of chemotherapy rituximab. However, her symptoms persisted and a repeat colonoscopy showed features consistent with ulcerative colitis. She received topical mesalazine and her symptoms resolved. Another repeat colonoscopy showed evidence of inactive chronic colitis only. This is a rare report of ulcerative colitis being diagnosed after rectal MALT was treated. It is possible that she might have long-standing ulcerative colitis that was undiagnosed, with the rectal MALT lymphoma masking the features of ulcerative colitis. A few treatment modalities are available, and the prognosis in general is good.
INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel disease (IBD) of unknown etiology. Over the past two decades, the epidemiology of IBD has changed, with the incidence rates of traditionally high incidence areas such as Europe and the United States remained relatively stable 1 , while IBD has become more prevalent in previously low incidence areas, such as Asia. According to the Asia-Pacific Crohn's and Colitis Epidemiology Study (ACCESS) 2 , the crude annual incidence (per 100,000 persons) of UC in Singapore was 0.4 (compared with the worldwide incidence rate of UC, which was between 0.5 and 24.5 per 100,000 persons 1 ). In Asia, there were more male than female patients with UC (57.9% vs 42.1%), and the peak age of diagnosis was 30 to 34 years old. Moreover, for UC, disease location was similar between Asia and Australia (proctitis, 37% vs 32%; left-sided colitis, 32% vs 27%; extensive/total colitis, 31% vs 41%).
Mucosa-associated lymphoid tissue (MALT) lymphomas were first described histologically by Isaacson and Wright in 1983 3 on primary gastrointestinal (GI) lymphomas. They are now classified as an extranodal marginal zone B cell lymphoma of MALT type according to the World Health Organization (WHO) classification system and account for approximately 8% of non-Hodgkin's lymphomas 4 . In MALT lymphomas, the gastrointestinal (GI) tract is the most common site of involvement (about 50% of MALT lymphomas) and within the GI tract, the stomach is the most common primary site (80-90% of gastric MALT lymphomas) 5 . Colorectal lymphomas are a rare tumour contributing to only 3% of the GI lymphomas 6 and 0.9-1.2% of all colorectal malignancies 7 .
We report a case of primary rectal MALT lymphoma in a middle-aged woman whose diagnosis of ulcerative colitis was made after she was treated for rectal MALT lymphoma.
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CASE REPORT
A 39-year old woman presented to the gastroenterology clinic with loose stool and rectal bleeding for one year. The abdominal exam was unremarkable. No rectal masses were felt. Proctoscopy showed haemorrhoids. A colonoscopy revealed proctitis ( Fig. 1 ). Biopsies were taken from the rectum only.
The rectal biopsy demonstrated destructive lymphoid infiltration with crypt effacement and extension through the thickened muscularis mucosae into the superficial submucosa.
The infiltrate was polymorphous, comprised predominantly sheets of mature plasma cells, small lymphocytes, monocytoid cells, and scattered, reactive (bcl-2-negative) germinal centres enclosed by eosinophils and relatively few neutrophils. The lymphoplasmacellular infiltrate was confluently positive for pan-B cell markers CD19, CD20, CD22, and CD79a. Immunohistochemical staining for cyclin D1 was negative. The infiltrate expressed a low cell proliferation fraction of 5-10% or less on Ki-67 immunolabelling, consistent with an indolent biology ( Fig. 2 ). There was monoclonal immunoglobulin demonstrated in the form of light Based on the histology and immnohistochemical staining, a diagnosis of rectal marginal B-cell lymphoma of MALT was made. Subsequently, she underwent a bone marrow aspiration and biopsy. Both flow cytometry and biopsy of the bone marrow specimen showed no evidence of any clonal B-lymphoproliferative disorder. The serum white blood cell count, serum lactate dehydrogenase (LDH) and ß2-microglobulin levels were normal. A computed tomography scan of the chest, abdomen and pelvis disclosed enlarged mesorectal lymph nodes, and smaller lymph nodes in the sigmoid mesocolon. There were no enlarged retroperitoneal, mediastinal or hilar lymph nodes. Because of the local nodal involvement, she had a stage IIE disease.
The haematologist discussed with her a few treatment options including surgery, radiotherapy, and rituximab. The side effects of each therapy were reviewed: surgery might be curative but the amount of rectum to be resected would be substantial which could result in significant morbidity; radiotherapy might be associated with radiation proctitis; rituximab might not be curative but could result in resolution of her symptoms. The side effects of rituximab including infusional reactions, infection, and neutropenia were discussed. The patient decided for rituximab which was given at 600 mg weekly for 4 weeks and she tolerated well. A computed tomography scan of the chest, abdomen and pelvis was performed 2 months after completion of chemotherapy and it demonstrated marginal reduction in the volume of the pelvic lymphadenopathy (mesorectal and sigmoid mesenteric nodes). However, her rectal bleeding persisted and hence a colonoscopy was performed. It revealed mucosal edema with loss of vascular pattern, friable tissue, and exudates affecting the rectum and sigmoid colon up to 20 cm from the anal verge ( Fig. 3 ).
Colonic biopsies did not demonstrate evidence of a MALT lymphoma. There were instead features compatible with ulcerative colitis, including mild crypt architectural distortion, mild basal lymphoplasmacytosis, acute inflammatory infiltrate associated with cryptitis, crypt abscess and focal erosion ( Fig. 4A ). She was treated as such with oral and topical mesalazine and her symptoms improved.
Another colonoscopy was performed 3 months later. There was improvement in the rectal inflammation, with mild loss of vascular pattern in the last 20 cm of the colon from anal verge ( Fig.  5 ). Colonic biopsies showed inactive chronic colitis (Fig. 4B ). She remained well on oral and topical mesalazine and her symptoms of rectal bleeding and mucus discharge all resolved.
DISCUSSION
Our patient's rectal MALT fulfilled the definition of a primary GI lymphoma suggested by Dawson et al. 8 in 1961 -the five components are: absence of palpable superficial lymph nodes on presentation; absence of enlarged mediastinal nodes on chest X-ray; normal range of total and differential white cell count; involvement of only regional lymph nodes, discovered on surgery; and no lymphomatous involvement of liver and spleen.
There was no separate classification for GI lymphomas under the WHO classification system 4 . GI lymphoma constitutes 30-40% of all primary extranodal lymphomas. The stomach is the most frequently involved site accounting for 60-70% of cases, followed by small bowel, ileocecum, colon and rectum. Mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma (DLBCL) are the prevailing histologies 9 Proceedings of Singapore Healthcare  Volume 24  Number 2  2015 lymphoma), and Helicobacter pylori (implicated in gastric MALT lymphoma)]. Despite the emerging data linking autoimmune/inflammatory conditions with lymphoma development, the exact pathways and mechanisms by which these lymphomas occur are yet to be defined. It is possible that B cells (or T cells) are exposed to and get activated by a range of antigens, leading to proliferation and clonal expansion, which in turn increases the risk of accumulating genetic events and ultimately results in development of an overt lymphoma 11 . Theoretically, the same concept may apply to IBD. However, multiple populationbased studies suggested that inflammatory bowel disease (IBD) is not associated with an increased risk of lymphoma 12, 13 . On the other hand, there is evidence that the use of thiopurines (azathioprine and 6-mercaptopurine) increases the risk of lymphoma in IBD patients: two meta-analyses 14, 15 and a prospective cohort study 16 all showed a fourto sixfold increase in risk. Our patient did not have the risk factors associated with the development of lymphoma as mentioned above. She was not known to have long-standing ulcerative colitis, nor was she on any immunomodulator treatment. Although her ulcerative colitis was apparently diagnosed after treatment of the rectal MALT, it is possible that she had long-standing ulcerative colitis which was just simply missed initially. There are three possible reasons to account for the current scenario. First, only rectal biopsies were taken during the first colonoscopy that showed proctitis. As inflammatory bowel disease is an important differential diagnosis to exclude, at least two biopsies from six segments (terminal ileum, ascending, transverse, descending, sigmoid and rectum) should be obtained. In addition, biopsies must be taken also from 'normal appearing' mucosa 17 which may indeed reveal chronic inflammation on histology. Second, the presence of MALT lymphoma could have masked the low grade chronic inflammation associated with UC. Third , the use of rituximab, an anti-CD20 monoclonal antibody, might exacerbate the UC which manifests right after the MALT lymphoma was treated. A few case reports have suggested that rituximab may cause 18 or aggravate UC 19 , possibly via B-cell depletion, leading to suppression of local interleukin (IL)-10 production that may protect against development of colitis 20 .
A literature search through PubMed from 1978-2014 was performed using the terms 'rectum' , 'mucosa associated lymphoid tissue' , 'lymphoma' , and 'ulcerative colitis' . There were only 45 published cases of primary rectal MALT lymphoma and one case of rectal MALT lymphoma and ulcerative colitis. The cases of rectal MALT lymphoma showed female predominance -out of the 45 cases, 14 were male. The age of diagnosis ranged from 19-80 (median age 62). Common presenting symptoms included rectal bleeding, tenesmus and abdominal pain. Some patients were asymptomatic at diagnosis, and they underwent further testing because of positive stool occult blood results. For the case report of rectal MALT lymphoma in ulcerative colitis 21 , the patient was a 19-year old woman with steroid dependent ulcerative colitis for 3 years. She underwent a three-stage proctocolectomy and ileal pouch-anal anastomosis. The proctectomy specimen showed MALT lymphoma in a background of ulcerative colitis. She received four cycles of CHOP (cyclophosphamide, adriamycin, vincristine and prednisolone) chemotherapy without significant Proceedings of Singapore Healthcare  Volume 24  Number 2  2015 toxicity. Follow-up endoscopy of the pouch and CT scan of the chest, abdomen and pelvis did not reveal any evidence of recurrence.
Given its rarity, optimal treatment modalities for rectal MALT were not established. The majority of cases of rectal MALT lymphoma reported were treated with the following: surgical resection (four cases), radiotherapy (eight cases), chemotherapy (five cases), antibiotic therapy against H. pylori (18 cases), endoscopic resection (two cases), combination of surgery and chemotherapy (two cases), combination of surgery and antibiotics (one case), combination of surgery and radiotherapy (one case), and combination of radiotherapy and chemotherapy (one case). In general, for earlystage extranodal marginal zone lymphoma of MALT, radiotherapy alone has been shown to be an effective treatment strategy for both localised gastric and non-gastric MALT lymphomas. Surgery can also be potentially curative. If resection margin is clear, these patients may be observed. Otherwise, for sites not amenable to surgery or if there is residual disease after surgery, radiotherapy should be considered. Rituximab is included as an option for selected patients in early stage, based on a phase II study 22 Although H. pylori (HP) eradication utilising antibiotic regimens is the standard first-line therapy for patients with HP-associated gastric MALT lymphoma, the role of antibiotic therapy in patients with non-gastric MALT lymphoma is less well defined. A series from Austria of 77 patients with extragastric MALT lymphomas showed that HP-eradication was ineffective for treatment of extragastric MALT lymphomas 23 . Our patient was not tested for HP infection status.
Mucosa-associated lymphoid tissue lymphomas overall have a good prognosis with a 5-year overall and failure-free survival of 81% and 65%, respectively . The National Comprehensive Cancer Network guidelines suggested that clinical followup (including repeat diagnostic tests and imaging based on the site of disease and as clinically indicated) should be conducted every 3-6 months for 5 years and then annually thereafter (or as clinically indicated).
CONCLUSION
In summary, we report a rare case of rectal MALT of which a diagnosis of ulcerative colitis was made after the patient was successfully treated with rituximab monotherapy. It is possible that she might have had long-standing ulcerative colitis that was undiagnosed, with the rectal MALT lymphoma masking the features of ulcerative colitis. A few treatment modalities are available, and the prognosis in general is good.
